Evidence map›Paper›PMID 41857430›Full record

ArticleInternational journal of hematology2026

Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.

Fumiaki Fujii, Masahiro Onozawa, Shota Yoshida, Naoki Miyashita, Daisuke Hidaka, Reiki Ogasawara, Mutsumi Takahata, Junichi Hashiguchi, Shota Yokoyama, Masahiro Chiba and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Fumiaki FujiiDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Masahiro OnozawaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan. masahiro.onozawa@gmail.com.ORCID http://orcid.org/0000-0001-9267-2864
Shota YoshidaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Naoki MiyashitaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Daisuke HidakaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Reiki OgasawaraDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Mutsumi TakahataDepartment of Hematology, Sapporo Kosei General Hospital, Sapporo, Japan.
Junichi HashiguchiDepartment of Internal Medicine/General Medicine, Kitami Red Cross Hospital, Kitami, Japan.
Shota YokoyamaDepartment of Hematology, Obihiro Kosei Hospital, Obihiro, Japan.
Masahiro ChibaDepartment of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
Tomoyuki SagaDepartment of Hematology, Kin-Ikyo Chuo Hospital, Sapporo, Japan.
Taku ShimizuDepartment of Hematology, Teine Keijinkai Hospital, Sapporo, Japan.
Ikumi KasaharaDepartment of Hematology, Sapporo City General Hospital, Sapporo, Japan.
Akio ShigematsuDepartment of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.
Katsuya FujimotoDepartment of Hematology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Satoshi IyamaDepartment of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Tetsuyuki IgarashiDepartment of Hematology, Tenshi Hospital, Sapporo, Japan.
Shinichi ItoDepartment of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
Yoshihito HaseyamaDepartment of Hematology, Tonan Hospital, Sapporo, Japan.
Mizuha Kosugi-KanayaAbbVie GK, Tokyo, Japan.
Takeshi KondoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venetoclax (VEN), a BCL-2 inhibitor, was approved in Japan in March 2021, for acute myeloid leukemia (AML). We retrospectively analyzed the impact of VEN approval on treatment patterns and outcomes in older AML patients aged 65-74 years unfit for intensive chemotherapy in Japan. Using the Hokkaido Leukemia Net database, we categorized 101 patients into pre-VEN (n = 46) and post-VEN (n = 55) cohorts, excluding those who had acute promyelocytic leukemia or received intensive chemotherapy. Following VEN approval, VEN + azacitidine (AZA) became the most frequently used initial regimen (56%). Despite higher rates of TP53 mutations and complex karyotypes (35.5%), VEN + AZA achieved comparable response rates (CR + CRi: 64.5%) and overall survival (OS, median 11.7 months) to r7 + 3 (CR + CRi: 64.5%, median OS: 13.1 months), and superior outcomes to cytarabine + aclarubicin + G-CSF (CAG, CR + CRi 37.5%, median OS 6.8 months) or AZA monotherapy (CR + CRi 12.5%, median OS 4.5 months). Early mortality at 60 days from diagnosis was lower with VEN + AZA (3.2%) than with reduced-dose cytarabine plus anthracycline (r7 + 3) (12.9%), CAG (26.7%), or AZA monotherapy (18.8%). Our findings demonstrate a substantial shift in real-world treatment practices following VEN approval and suggest that VEN + AZA is an effective option for older AML patients with adverse genetic features.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAclarubicinAgedAzacitidineCytarabineFemaleGranulocyte Colony-Stimulating FactorHumansJapanMaleMutationRetrospective StudiesSurvival RateAclarubicinAzacitidineBridged Bicyclo Compounds, HeterocyclicCytarabineGranulocyte Colony-Stimulating FactorSulfonamidesvenetoclaxAcute myeloid leukemiaAzacitidineElderly patientsTreatment patternsVenetoclax

Identifiers

PMID41857430
PMCPMC13407739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.